Description
Clinical decision support system (CDSS) plays a significant role nowadays and it assists physicians in making decisions for treatment. Generally based on clinical guideline, the principles of the recommendation are provided and may suggest several candidate medications for similar patient group with certain clinical conditions. However, it is challenging to prioritize these candidates and even refine the guideline to a finer level for patient-specific recommendation. Here we propose a method and system to integrate the clinical knowledge and real-world evidence (RWE) for type 2 diabetes treatment, to enable both standardized and personalized medication recommendation. The RWE is generated by medication effectiveness analysis and subgroup analysis. The knowledge model has been verified by clinical experts from the advanced hospitals. The data verification results show that the medications that are consistent with the method recommendation can lead to better clinical outcome in terms of glycemic control, compared to those inconsistent.
Learning Objective: Understand the current issues in CDSS treatment, including the lack of patient-specific decisions and effectiveness analysis, and be able to propose a method and system to integrate the clinical knowledge and real-world evidence (RWE) for type 2 diabetes treatment, enabling both standardized and personalized medication recommendation.
Authors:
Xingzhi Sun (Presenter)
Ping An Health Technology, Beijing, China
Wei Zhao, Ping An Health Technology, Beijing, China
Lei Zuo, Ping An Health Technology, Beijing, China
Alexandra Dumitriu, Sanofi
Chuang-Chung LEE, Sanofi
Nan Cui, Sanofi (China) Investment
Xiyang Liao, Ping An Health Technology, Beijing, China
Tingting Zhao, Ping An Health Technology, Beijing, China
Xuehan Jiang, Ping An Health Technology, Beijing, China
Zhuoyang Xu, Ping An Health Technology, Beijing, China
Gang Hu, Ping An Health Technology, Beijing, China
Guotong Xie, Ping An Health Technology, Beijing, China
Hong WU, Sanofi (China) Investment
Yahua Huang, Sanofi (China) Investment
Presentation Materials: